BACKGROUND Lipid-lowering therapeutics, particularly HMG Co-A reductase inhibitors, can be beneficial in primary and secondary cardiovascular prevention. The Canadian population frequently uses these medications but the manner in which they are used in community-based practice is unknown. OBJECTIVES To assess the patient characteristics associated with lipid lowering drug use in community-bas...

BACKGROUND For patients with diabetes, clinical practice guidelines recommend treating to a low-density lipoprotein cholesterol (LDL-C) goal of < 2.59 mmol/L (100 mg/dL) and a blood pressure (BP) target of <130/80 mmHg. This analysis assessed recent trends in the utilization of lipid-lowering and BP-lowering agents, as well as LDL-C and BP goal attainment, in the U.S. adult diabetic population....

Background. Dementia and cardiovascular disease (CVD) are frequently comorbid. The presence of dementia may have an effect on how CVD is treated. Objective. To examine the effect of dementia on the use of four medications recommended for secondary prevention of ischemic heart disease (IHD): angiotensin-converting enzyme inhibitors, beta-blockers, lipid-lowering medications, and antiplatelet med...

The benefits of aggressive lipid-lowering therapy in reducing long-term cardiovascular morbidity and mortality have been firmly established, both in patients with established stable coronary artery disease (CAD) and in high-risk patients without clinically apparent CAD. Although lipid-lowering agents, in particular the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statin...

statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of hmg-co a reductase. apart from the well-known ldl and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. better understanding of various pleotropic effects of statins has prompted a new s...

the present study was aimed at evaluating the lipid lowering activity of lercanidipine, a calcium channel blocker, in standard diet induced hyperlipidemic rats. hyperlipidemic rats were divided into different groups and were treated with daily oral dose of lercanidipine and atorvastatin for 7 days. on 8 th day, blood samples were collected and analyzed for serum lipid levels using commercial ki...

Reduction in low-density lipoprotein cholesterol (LDL-C) is associated with a decrease in coronary heart disease (CHD). Statins are currently the most effective medications for LDL-C lowering; however, there continues to be a residual risk for cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that promotes LDL receptor degradation, leading to an increase...